Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 1.59 is 54% below its 1-year average of 3.47, near the low end of its 1-year range (0.00–8.10).
As of the fiscal period ended Tuesday, June 30, 2026. 50.07% below its 12-month average of 3.18.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.59.
DEBT TO EQUITY RATIO
1.59
DEBT TO EQUITY RATIO AVG TTM
3.18
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-50.07%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 771 covered companies
CURRENT VS SECTOR MEDIAN
+1341.62%
vs the sector median at left
Lumexa Imaging Holdings, Inc. Common Stock
Market Cap
$1.02B
Debt to Equity Ratio
1.59
TTM Avg
3.18
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.03B
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.05
5Y Avg
0.03
Market Cap
$1.01B
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$1.03B
Debt to Equity Ratio
1.94
TTM Avg
1.61
3Y Avg
1.30
5Y Avg
1.21
Market Cap
$1.03B
Debt to Equity Ratio
0.08
TTM Avg
0.07
3Y Avg
0.05
5Y Avg
0.04
Market Cap
$997.29M
Debt to Equity Ratio
N/A
TTM Avg
0.29
3Y Avg
0.20
5Y Avg
0.20
Market Cap
$990.72M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$984.90M
Debt to Equity Ratio
0.52
TTM Avg
0.95
3Y Avg
0.70
5Y Avg
0.50
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI) | $1.02B | 1.59 | 3.18 | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.02B | 0.04 | 0.03 | 0.05 | 0.11 |
| Janux Therapeutics, Inc. (JANX)vs › | $1.03B | 0.02 | 0.02 | 0.05 | 0.03 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | 0.01 | 0.01 | 0.01 | 0.01 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | 1.94 | 1.61 | 1.30 | 1.21 |
| Castle Biosciences, Inc. (CSTL)vs › | $1.03B | 0.08 | 0.07 | 0.05 | 0.04 |
| Vor Biopharma Inc. (VOR)vs › | $997.29M | N/A | 0.29 | 0.20 | 0.20 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $990.72M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $984.90M | 0.52 | 0.95 | 0.70 | 0.50 |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $984.70M | 0.23 | 0.21 | 0.27 | 0.36 |
Debt/Equity
1.59
Current Ratio
1.44
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 1.59 |
| 2026-03-31 | 1.61 |
| 2025-12-31 | 1.64 |
| 2025-09-30 | 7.86 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 8.10 |
